rs12044149 — IL23R

Regulatory variant upstream of the IL-23 receptor gene more strongly associated with psoriatic arthritis than cutaneous psoriasis alone, implicating distinct Th17 signaling at the joint versus skin interface

See your personal result for IL23R

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL23R — When the Psoriasis Gene Targets Joints More Than Skin

The IL23R11 IL23R
interleukin-23 receptor gene, chromosome 1p31.3; encodes the ligand-binding subunit of the IL-23 receptor complex that pairs with IL-12Rβ1 on Th17 cells, NK cells, and innate lymphoid cells gene has yielded multiple independent susceptibility variants for psoriatic disease, and rs12044149 is one of the most instructive. Unlike the well-known intronic IL23R variants that associate broadly with psoriasis, psoriatic arthritis, and inflammatory bowel disease, rs12044149-T shows a strikingly specific enrichment for psoriatic arthritis22 psoriatic arthritis
a chronic inflammatory arthritis affecting up to 30% of people with psoriasis, characterized by synovitis, enthesitis, dactylitis, and progressive joint damage; distinct from rheumatoid arthritis in its asymmetric distribution and nail/skin involvement over cutaneous-only psoriasis — suggesting that variation in IL-23 receptor regulation at this upstream locus differentially modulates joint versus skin inflammatory programs.

The Mechanism

rs12044149 sits at GRCh38 chr1:67,135,003, approximately 3.6 kb upstream of the IL23R transcription start site, within an intron of the poorly-characterized C1orf141 gene. Its position in the regulatory landscape of IL23R makes it a candidate cis-regulatory variant33 cis-regulatory variant
a variant that affects expression or splicing of a nearby gene in cis (same chromosome), typically by altering transcription factor binding sites, enhancer activity, or chromatin accessibility in the locus that subtly modulates IL23R expression or activity at the joint-specific immune interface.

IL-23R signals through JAK2 and STAT344 JAK2 and STAT3
Janus kinase 2 and Signal Transducer and Activator of Transcription 3 — the immediate downstream effectors of IL-23 receptor engagement; pSTAT3 drives expression of RORγt, the master Th17 transcription factor to expand and sustain Th17 cell populations. In psoriatic arthritis, IL-23-stimulated Th17 cells produce IL-17A and IL-17F at the synovial interface, promoting: - RANKL-mediated osteoclast activation and bone erosion - Synoviocyte hyperplasia and pannus formation - Entheseal inflammation (tendon/ligament insertions — a hallmark of PsA) - Dactylitis ("sausage digits") from combined synovial and periarticular inflammation

The articular specificity of rs12044149-T likely reflects the distinct cytokine milieu of synovial tissue versus the epidermis. Synovial dendritic cells and macrophages may amplify IL-23 signals differently from skin-resident cells, and a variant that shifts IL23R expression even modestly at this joint-specific interface could selectively tip the balance toward arthritis over skin plaque formation.

The Evidence

The initial identification of rs12044149 came from a landmark GWAS meta-analysis comparing psoriatic arthritis to cutaneous-only psoriasis55 landmark GWAS meta-analysis comparing psoriatic arthritis to cutaneous-only psoriasis
Stuart et al. 2015, American Journal of Human Genetics; 9,293 psoriasis-spectrum case subjects, 3,061 PsA cases, 3,110 cutaneous-only psoriasis cases, 13,670 controls, all European descent. This study was specifically designed to dissect the genetics of the PsA/PsC split. The rs12044149-T allele near IL23R reached p = 0.00018 with stronger association in PsA than PsC, and crucially, this signal was independent of the previously identified psoriasis variants at the IL23R locus (notably rs2201841) — meaning rs12044149 tags a distinct component of IL23R biology relevant specifically to arthritis development.

The association was substantially strengthened in a large-scale comparative genetic analysis66 large-scale comparative genetic analysis
Soomro et al. 2022, Arthritis & Rheumatology; 5,065 PsA patients, 21,286 healthy controls, and 6,431 cutaneous-only psoriasis patients, which confirmed the rs12044149-T association with PsA at p = 4×10⁻²⁰, OR 1.27 (95% CI 1.20–1.33). A risk allele frequency of 0.26 in this study is consistent with the global T allele frequency of ~24%. The genome-wide significance and large sample size places this association firmly in the strong evidence tier.

The broader IL23R locus context is established by meta-analyses of IL23R variants77 meta-analyses of IL23R variants
Zhu et al. 2012, Inflammation Research — 13 studies confirming IL23R association with psoriasis and PsA: the IL-23 pathway is one of the most genetically validated axes in psoriatic disease, and rs12044149 adds to this locus by tagging the articular-specific component that other IL23R variants do not fully capture.

Practical Actions

The primary clinical significance of rs12044149-T is as an early-warning marker for psoriatic arthritis risk, particularly in individuals who already have — or are at risk for — cutaneous psoriasis. An OR of 1.27 per T allele means TT homozygotes (roughly 6% of Europeans) carry approximately 1.6-fold elevated PsA risk relative to GG homozygotes under an additive model.

No pharmacogenomic guideline currently links rs12044149 to differential response to IL-23 inhibitors (risankizumab, guselkumab) or IL-17 inhibitors (secukinumab, ixekizumab). However, the biological rationale for IL-23/IL-17 pathway therapies in PsA is strong, and these agents are now first-line options for active PsA with inadequate response to conventional DMARDs. The genotype contextualizes the pathway being targeted without yet predicting which specific agent will perform best.

Early detection of psoriatic arthritis matters enormously: joint damage begins within months of disease onset and is irreversible. The window between first articular symptoms and diagnosis currently averages 1.5–2.5 years — a gap that genotype-informed awareness can help close.

Interactions

rs12044149 operates in the same IL-23/Th17 corridor as several other variants in the GeneOps database. rs2201841 (IL23R, intronic) is the principal psoriasis/IBD susceptibility locus at IL23R — the two variants appear to be independent signals at the same locus, tagging different regulatory elements with different tissue emphases. The Stuart 2015 study explicitly confirmed rs12044149's independence from rs2201841 in the joint-disease signal.

rs33980500 (TRAF3IP2/Act1 D10N) is the downstream IL-17 signaling adaptor variant most strongly associated with psoriatic arthritis — its risk allele is highly specific to PsA over cutaneous psoriasis, making it a natural companion marker to rs12044149 at the receptor level. Together, they may tag individuals with both enhanced IL-23 input and heightened IL-17 downstream responsiveness in joint tissue.

rs9321623 near TNFAIP3 was co-identified in the same Stuart 2015 GWAS as a second PsA-specific locus; individuals carrying risk alleles at both rs12044149 and rs9321623 may have additive susceptibility to articular psoriatic disease through complementary NF-κB and IL-23 pathway dysregulation.

Genotype Interpretations

What each possible genotype means for this variant.

GG Typical IL-23R Upstream Activity Normal

Common genotype — no elevated IL-23R-mediated psoriatic arthritis risk from this variant

You carry two copies of the G reference allele at rs12044149, the most common genotype globally (approximately 57% of people of European descent). This genotype is associated with typical regulatory activity at the IL23R locus and does not contribute elevated genetic risk for psoriatic arthritis through this specific variant. About 75% of all chromosomes carry the G allele, making it the clear population majority in all major ancestry groups.

GT One Risk Copy Intermediate

One T risk allele — modestly elevated psoriatic arthritis susceptibility through IL23R

The T allele at rs12044149 was identified specifically because it differentiates psoriatic arthritis from cutaneous-only psoriasis within the same IL23R locus — a notable finding, since most IL23R variants associate with both skin and joint disease. This means the T allele likely modulates a joint-specific aspect of IL-23 receptor biology: possibly synovial IL23R expression, dendritic cell IL-23 production in the joint microenvironment, or entheseal Th17 activation thresholds.

At the heterozygous level, the effect is intermediate. The full OR of 1.27 is the per-T-allele estimate; GT heterozygotes carry one copy, so their risk increment is approximately half of the TT-minus-GG difference under strict additivity.

TT Two Risk Copies High Risk

Homozygous T allele — elevated genetic susceptibility to psoriatic arthritis via IL23R

The TT genotype places you at the highest end of the rs12044149-attributable susceptibility for psoriatic arthritis. The original discovery study (Stuart et al. 2015) was the first to identify this variant as PsA-specific rather than a general psoriasis susceptibility locus, and subsequent large-scale replication (Soomro et al. 2022, n >26,000) confirmed genome-wide significance (p = 4×10⁻²⁰) with a consistent OR of 1.27 per T allele.

The articular specificity is clinically actionable in a way that generic IL23R risk is not: if you have psoriasis, this genotype specifically flags you as higher-risk for the articular complication rather than simply for skin severity. Psoriatic arthritis affects approximately 20–30% of psoriasis patients overall, but the baseline prevalence in T-allele homozygotes is likely higher.

The IL-23 pathway this variant tags is directly targeted by approved biologics: IL-23 inhibitors (risankizumab/Skyrizi, guselkumab/Tremfya) and the dual IL-12/23 inhibitor ustekinumab/Stelara are all approved for both psoriasis and psoriatic arthritis. IL-17 inhibitors (secukinumab/Cosentyx, ixekizumab/Taltz, bimekizumab/Bimzelx) target the downstream effector cytokine. While rs12044149 does not yet predict differential response among these agents, your genotype confirms you are operating within the biologically most druggable axis of psoriatic disease.